期刊文献+

180例野生型胃肠间质瘤患者的临床病理特征分析 被引量:16

Analysis of clinicopathological characteristics in 180 patients with wild type gastrointestinal stromal tumors
原文传递
导出
摘要 目的:大样本分析中国野生型胃肠间质瘤(GIST)患者的临床病理特征。方法收集2001年10月至2013年9月于北京大学肿瘤医院就诊的180例野生型胃肠间质瘤患者的临床病理资料,分析野生型GIST患者的临床病理特征,并与同时期的临床病理资料较完整的513例突变型GIST患者进行比较。结果180例野生型GIST患者中,男女比例1∶1,中位年龄52.5(16~78)岁。肿瘤原发于胃者82例(45.6%),小肠43例(23.9%),结直肠21例(11.7%),另有34例(18.9%)患者肿瘤发生于腹腔、盆腔、网膜和肾周等其他部位。50岁以下患者中肿瘤长径大于5 cm的比例明显高于50岁以上患者[77.2%(61/79)比54.9%(50/91),P<0.01];且肿瘤大小与核分裂象具有显著关联(P<0.01)。CD117阳性率为81.7%(138/169),DOG-1阳性率为75.6%(62/82),CD34阳性率为74.7%(115/154);3种因子均于胃GIST中阳性率最高。与突变型GIST患者比较,野生型GIST发生于年轻患者和原发于胃者比较更高,肿瘤相对更小,CD117和DOG-1阳性率相对较低(均P<0.01)。结论野生型与突变型GIST在发病年龄、发病部位、肿瘤大小及CD117、DOG-1表达率方面存在明显差异,提示野生型GIST可能作为一个独立的亚型,在临床治疗中需特别关注。 Objective To investigate the clinicopathological characteristics of 180 patients with wild type gastrointestinal stromal tumors (GIST). Methods The clinicopathological data of 180 patients with wild type GIST treated in the Peking University Cancer Hospital between October 2001 and September 2013 were analyzed and compared to 513 mutant patients. Results 180 patients were included in this study, and the median age 52.5 years (16-78 years). The percentage of female was significantly higher than that of male among patients under the age of 40 . Primary tumor sites mainly included stomach (45.6%) and small intestine (23.9%). The positive expression of CD117, DOG-1, and CD34 were 81.6%, 75.6%, and 74.7%, respectively, which were highest in stamach, secondly in small intestine. The percentage of tumor with length 〉 5 cm was higher in patients under the age of 50 compared to patients more than 50 years, and a significant correlation was found between tumor size and mitosis. Compared to mutant patients, wild type patients had the following features: younger, primary tumor site of stomach, tumor length ≤2 cm, and the lower positive expression of CD117 and DOG-1. Conclusions The significant differences in primary tumor sites, tumor size, and the positive expression of CD117/DOG-1 were found between wild type GIST and mutant GIST , which suggested
出处 《中华胃肠外科杂志》 CAS CSCD 北大核心 2015年第4期342-345,共4页 Chinese Journal of Gastrointestinal Surgery
基金 北京市自然科学基金(7122031)
关键词 胃肠间质瘤 野生型 临床病理特征 Gastrointestinal stromal tumors Wild type Clinicopathological characteristic
  • 相关文献

参考文献2

二级参考文献18

  • 1毕建威,经纬,魏国,苏明,唐晓军.胃肠道间质瘤46例临床诊治分析[J].中国实用外科杂志,2005,25(11):684-685. 被引量:20
  • 2杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299. 被引量:49
  • 3Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7:507-519.
  • 4Schaldenbrand JD, Appelman HD. Solitary solid stromal gastrointestinal tumors in yon Recklinghausen's disease with minimal smooth muscle differentiation. Hum Pathol 1984;15; 229-232.
  • 5Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-1269.
  • 6Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J,Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP,Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459-465.
  • 7Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33;484-495.
  • 8Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R,Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD,Fletcher CD, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61;8118-8121.
  • 9Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R,Nassar A, Sobin LH, Miettinen M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors.A study of 200 cases. Am J Pathol 2000; 157:1091-1095.
  • 10Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J,Okazaki T, Kitamura Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromaltumours. J Pathol 2001; 193:505-510.

共引文献40

同被引文献145

  • 1Takuya Wada,Satoshi Tanabe,Kenji Ishido,Katsuhiko Higuchi,Tohru Sasaki,Chikatoshi Katada,Mizutomo Azuma,Akira Naruke,Myunguchul Kim,Wasaburo Koizumi,Tetsuo Mikami.DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach[J].World Journal of Gastroenterology,2013,19(47):9133-9136. 被引量:11
  • 2Chin-Yuan Tzen,Bey-Liing Mau.Analysis of CD117-negative gastrointestinal stromal tumors[J].World Journal of Gastroenterology,2005,11(7):1052-1055. 被引量:14
  • 3杜春燕,师英强,傅红,赵广法,周烨,蔡国响.胃肠道间质瘤103例预后分析[J].中国实用外科杂志,2007,27(4):297-299. 被引量:49
  • 4何裕隆.胃肠间质瘤临床病例解析[J].国际外科学杂志,2007,34(5):354-358. 被引量:12
  • 5刘艳君,王学梅.胃肠道间质瘤的超声检查与病理检查对比分析[J].中国医科大学学报,2007,36(4):480-482. 被引量:8
  • 6Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis[J]. Am 1 Surg Pathol, 1983,7(6) :507-519.
  • 7Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].Science, 1998,279(5350) :577-580.
  • 8Demetri GO, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl 1 Med, 2002,347(7):472-480.
  • 9Blanke CD, Rankin C, Demetri GO, et al. Phase ill randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J]. 1 Clin Oncol, 2008,26(4):626-632. 001: 10. 120011CO.2007. 13.4452.
  • 10Verweij 1, Casali PG, Zalcberg 1, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib , randomised trial [J]. Lancet, 2004,364 (9440) :1127- 1134.

引证文献16

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部